Finance
Roche earnings edge up 5% as forex effects weigh on drug sales growth
Published by Global Banking & Finance Review®
Posted on January 29, 2026
1 min readLast updated: January 29, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on January 29, 2026
1 min readLast updated: January 29, 2026
Roche forecasts high single-digit earnings growth and mid single-digit sales growth by 2026, as announced in Frankfurt.
By Ludwig Burger
FRANKFURT, Jan 29 (Reuters) - Roche's full-year adjusted operating income rose by a lower-than-expected 5% as gains in drugs such as Phesgo against breast cancer and Hemlibra against haemophilia were partly offset by a weak U.S. dollar weighing on overseas sales.
Operating profit, adjusted for special items, came in at 21.8 billion Swiss francs ($28.5 billion) in 2025, the Swiss drugmaker said in a statement on Thursday, just shy of a market consensus of 22 billion francs cited by analysts.
The group also said it expects 2026 group sales to grow in the mid single-digit percentage range, while targeting core earnings per share growth in the high single-digit range.
(Reporting by Ludwig Burger, Editing by Friederike Heine)
Core earnings are the profits generated from a company's primary business operations, excluding any income from non-operational activities like investments or sales of assets. They provide a clearer picture of operational performance.
Group sales refer to the total revenue generated by a company from all its business segments combined. It reflects the overall market performance and demand for the company's products or services.
A financial projection is an estimate of a company's future financial performance, including revenue, expenses, and profits. It is based on historical data and market analysis, helping businesses plan and make informed decisions.
Explore more articles in the Finance category
